PMID- 20139052
OWN - NLM
STAT- MEDLINE
DCOM- 20101007
LR  - 20191210
IS  - 1658-3876 (Print)
IS  - 2589-0646 (Linking)
VI  - 2
IP  - 3
DP  - 2009
TI  - Validation of tissue microarray biomarker expression of breast carcinomas in 
      Saudi women.
PG  - 394-8
AB  - BACKGROUND: Analysis of immunohistochemical expression of a large number of tumor 
      tissue samples with conventional techniques is costly, tedious and slow. Tissue 
      microarray (TMA) technology can facilitate the sampling of over 500 tumors on a 
      one-glass slide, which then can be analyzed by fluorescence in situ hybridization 
      (FISH), RNA in situ hybridization, or immunohistochemistry. We attempted to 
      validate this technique in breast cancer specimens by comparing the staining 
      result obtained by TMA with the conventional whole-section method. PATIENTS AND 
      METHODS: Eighty cases of breast cancer of diverse subtypes were used to build a 
      breast cancer biomarker evaluation model. Serial sections of the recipient block 
      were immunostained with a panel of 4 anti- bodies (ER, PR, HER2 and p53). 
      Concordance of immunohistochemical expression between TMA sections and 
      whole-sections was expressed as a kappa statistic. RESULTS: Target tumors were 
      accurately sampled by two cores in 19 of 26 donor blocks, and by only one core in 
      5 blocks. Failure to sample tumor was seen in 2 blocks. Concordance between the 
      staining results of TMA and whole sections was good for PR (kappa=0.67) and ER 
      (kappa=0.67) and very good for p53 (kappa=0.91) and HER2 (kappa=0.91), when all 
      the 26 recipient blocks were included. The rate improved to excellent for p53 
      (kappa=1.0) and did not change for the other markers when concordance analysis 
      was limited to recipient blocks that had been sampled by two cores. CONCLUSION: 
      TMA is a reliable technique for examining a large set of tumors. It shows 
      immunostaining scores comparable to those obtained by conventional whole-section 
      evaluation in breast cancer. However, some alterations are not detected due to 
      heterogeneity of biomarker expression inherent in these tumors, but this 
      shortfall can be improved.
FAU - Alkushi, Abdulmohsen
AU  - Alkushi A
AD  - Department of Pathology and Laboratory Medicine, King Saud bin Abdulaziz 
      University for Health Sciences, Riyadh, Saudi Arabia. kushia@ngha.med.sa
LA  - eng
PT  - Journal Article
PT  - Validation Study
PL  - Saudi Arabia
TA  - Hematol Oncol Stem Cell Ther
JT  - Hematology/oncology and stem cell therapy
JID - 101468532
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Breast Neoplasms/*metabolism/pathology
MH  - Carcinoma, Ductal, Breast/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Prognosis
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Saudi Arabia
MH  - *Tissue Array Analysis
MH  - Tumor Suppressor Protein p53/metabolism
EDAT- 2010/02/09 06:00
MHDA- 2010/10/12 06:00
CRDT- 2010/02/09 06:00
PHST- 2010/02/09 06:00 [entrez]
PHST- 2010/02/09 06:00 [pubmed]
PHST- 2010/10/12 06:00 [medline]
AID - 09-394 [pii]
AID - 10.1016/s1658-3876(09)50007-6 [doi]
PST - ppublish
SO  - Hematol Oncol Stem Cell Ther. 2009;2(3):394-8. doi: 
      10.1016/s1658-3876(09)50007-6.